A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.
For prevention of HIV infection many currently licensed anti-HIV drugs and new ones in the pipeline show potential as topically applied microbicides. While macaque models have been the gold standard for in vivo microbicide testing, they are expensive and sufficient numbers are not available. Therefo...
Main Authors: | C Preston Neff, Theresa Kurisu, Thomas Ndolo, Kami Fox, Ramesh Akkina |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3105981?pdf=render |
Similar Items
-
Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.
by: C Preston Neff, et al.
Published: (2010-12-01) -
Maraviroc – a CCR5 antagonist for the treatment of HIV-1 infection
by: Elna eVan Der Ryst
Published: (2015-06-01) -
Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens
by: A V Kravchenko
Published: (2013-11-01) -
Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model.
by: Laura Ochoa-Callejero, et al.
Published: (2013-01-01) -
Humanized Rag1-/- γc-/- mice support multilineage hematopoiesis and are susceptible to HIV-1 infection via systemic and vaginal routes.
by: Ramesh Akkina, et al.
Published: (2011-01-01)